AbbVie opens the week with a full earnings calendar, shares trade steadily on the NYSE
30.06.2026 - 10:33:41 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-30, 10:33.
AbbVie Inc. (US00287Y1091) starts this week with a clear earnings calendar as investors look ahead to its next quarterly report on the NYSE. The big pharma group sits in the S&P 500 and is widely covered by Wall Street research houses that track its dividend and cash flow profile.
What consensus numbers suggest
Analyst coverage on AbbVie is broad, with major Wall Street firms such as Goldman Sachs, JPMorgan and Morgan Stanley maintaining regular updates on the stock. Many houses focus on the company’s established cash-generating franchises in immunology and neuroscience when setting their earnings and revenue forecasts.
Consensus estimates compiled from sell-side models typically reflect expectations for mid-single-digit to low-double-digit percentage revenue growth in coming years, driven by newer products offsetting patent expiries on legacy drugs. Earnings-per-share projections often factor in ongoing share repurchases and a progressive dividend policy that has appealed to income-oriented investors.
Upcoming earnings and calendar focus
AbbVie follows a standard U.S. reporting cycle, with quarterly results traditionally scheduled around late July or early August for its second quarter and late October or early November for the third quarter. Investors watch the company’s investor relations calendar closely for the precise earnings date, conference call times and any planned participation in healthcare conferences.
On typical earnings days, AbbVie provides a detailed breakdown of product-level sales, margins and guidance through its press release and management commentary. Retail investors often pay attention to whether management adjusts full-year guidance or confirms prior outlooks, since such moves can signal confidence or caution on the trajectory of key product launches.
All news and analysis on the AbbVie shares
For further company updates, price data and background on AbbVie, the thematic page offers a consolidated view of recent developments.
The business behind AbbVie
AbbVie generates most of its revenue from pharmaceuticals in immunology, oncology, neuroscience, eye care and aesthetics. Historically, its largest product contribution came from Humira, an anti-TNF biologic for autoimmune diseases such as rheumatoid arthritis and Crohn’s disease, though patent expiry has shifted the mix toward newer drugs.
More recently, the company has emphasized growth from immunology therapies like Skyrizi and Rinvoq, which target psoriasis and rheumatoid arthritis, and from neuroscience products including Botox Therapeutic and Vraylar. In aesthetics, Botox Cosmetic and Juvederm provide additional cash flow streams that diversify AbbVie’s earnings profile beyond traditional prescription drugs.
Where the AbbVie stock trades today
AbbVie shares (US00287Y1091) trade on the New York Stock Exchange in U.S. dollars. As of 2026-06-30, 10:33, the latest indicative price and market capitalization data are sourced from standard exchange feeds, with intraday movements reflecting broader S&P 500 healthcare sector trends.
AbbVie at a glance
- Company: AbbVie Inc.
- ISIN: US00287Y1091
- WKN: A1H6V7
- Ticker: ABBV
- Trading venue: NYSE
- Price (as of 2026-06-30, 10:33): latest indicative price in USD
- Market cap: large-cap U.S. dollars figure (as of 2026-06-30)
- Sector / industry: Pharmaceuticals / Biotechnology
- Index membership: S&P 500
- Next earnings date: not officially scheduled
This article is for informational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any securities. All data are based on publicly available information believed to be reliable but not guaranteed.
